Literature DB >> 8558920

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

W G Dirks1, M Zaborski, K Jäger, C Challier, M Shiota, H Quentmeier, H G Drexler.   

Abstract

The CD30+ anaplastic large cell lymphoma (ALCL) represents a new lymphoma entity thought to be related to Hodgkin'S disease (HD), but displaying also its own unique features. Cytogenetic studies of ALCL have demonstrated the presence of a (2;5)(p23;q35) translocation in a substantial number of these cases. Recently, the t(2;5) has been cloned and described to represent fusion of the NPM gene with the ALK gene on chromosome 5. To better define the spectrum of lymphomas containing this abnormality we have analyzed 50 continuous human cell lines established from various types of non-Hodgkin's lymphoma, ALCL and HD. In a first step, the expression of the NPM-ALK fusion gene was examined by reverse transcriptase-polymerase chain reaction (RT-PCR). In a second step, the t(2;5)-carrying cells were tested for the translation of functional chimeric mRNA into a fusion protein by immuno-staining of single cells with a polyclonal antibody. The NPM-ALK fusion transcript and the p80 protein were detected in eight of nine ALCL cell lines. We were unable to find PCR evidence for the t(2;5) in any of the non-ALCL cell lines including other CD30+ cell lines. As all seven bona fide HD cell lines were NPM-ALK-negative, these results do not support the notion that the t(2;5) represents a chromosomal aberration common to both ALCL and HD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558920

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.

Authors:  S Li; D T Ross; M E Kadin; P O Brown; M A Wasik
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context.

Authors:  Maria A Theodoraki; Mary Kunjappu; David W Sternberg; Avrom J Caplan
Journal:  Exp Cell Res       Date:  2007-07-06       Impact factor: 3.905

3.  Proteome activity landscapes of tumor cell lines determine drug responses.

Authors:  Martin Frejno; Chen Meng; Benjamin Ruprecht; Thomas Oellerich; Sebastian Scheich; Karin Kleigrewe; Enken Drecoll; Patroklos Samaras; Alexander Hogrebe; Dominic Helm; Julia Mergner; Jana Zecha; Stephanie Heinzlmeir; Mathias Wilhelm; Julia Dorn; Hans-Michael Kvasnicka; Hubert Serve; Wilko Weichert; Bernhard Kuster
Journal:  Nat Commun       Date:  2020-07-20       Impact factor: 14.919

4.  Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.

Authors:  Pierre Mélard; Yamina Idrissi; Laetitia Andrique; Sandrine Poglio; Martina Prochazkova-Carlotti; Sabine Berhouet; Cécile Boucher; Elodie Laharanne; Edith Chevret; Anne Pham-Ledard; Andréa Carla De Souza Góes; Véronique Guyonnet-Duperat; Alice Bibeyran; François Moreau-Gaudry; Béatrice Vergier; Marie Beylot-Barry; Jean-Philippe Merlio; David Cappellen
Journal:  Oncotarget       Date:  2016-10-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.